The goal of this exploratory clinical trial is to evaluate the efficacy and safety of a test spectacle lens (standard single vision lens (SVL) during first year, and standard myopia control lens (MCL) in second year), designed with passive red-light emission, for the control of myopia progression in myopic children age 6 to 11 years old, both male and female, with no systemic or ocular anomalies. The main question it aims to answer is:

Does the test spectacle lens designed with passive red-light emission provide significant myopia control effect to children?

Researchers will compare the standard SVL designed with passive red-light emission to SVL (first year) and MCL designed with passive red-light emission to MCL (second year) to see if the test spectacle lens work to slow down myopia progression.

Participants will:

• Wear the study spectacles
• Visit Essilor R&D Centre for follow-up sessions

Inclusion Criteria:

• Children equal to or greater than 6 years old and less than 11 years at the time of signing informed consent.
• Corrected spherical equivalent refraction (SER) between -0.75 D and -5.00 D with astigmatism not more than 2.50 D.
• Difference in SER (Anisometropia) between two eyes should not exceed 1.00 D.
• Best corrected visual acuity better than or equal to +0.10 log MAR (20/25 or better with Snellen).
• Be in good general health, based on his/her and parent's/guardian's knowledge.
• Agree to wear spectacles for >12 hours/day and at least 6 days/week.
• Willingness and ability to participate in investigation for 2 years and attend scheduled visits.

Exclusion Criteria:

• Any ocular or systemic pathologies known to affect refractive status (e.g. keratoconus, diabetes, Down's syndrome etc.)
• Any binocular vision anomalies
• Amblyopia
• Use of prior myopia control treatment like specialized myopia control spectacles and contact lenses at least in the previous one month.
• Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.
• Participation in any clinical investigation within 30 days of the baseline visit.